These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24275854)

  • 1. Reactivation of p53 as therapeutic intervention for malignant melanoma.
    Jochemsen AG
    Curr Opin Oncol; 2014 Jan; 26(1):114-9. PubMed ID: 24275854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy.
    Lu M; Miller P; Lu X
    FEBS Lett; 2014 Aug; 588(16):2616-21. PubMed ID: 24844434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK'ing the most of p53 reactivation therapy in melanoma.
    Lee JT; Herlyn M
    J Invest Dermatol; 2012 Feb; 132(2):263-5. PubMed ID: 22241441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
    Hsieh CC; Shen CH
    Curr Treat Options Oncol; 2019 Feb; 20(3):22. PubMed ID: 30778775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
    Dummer R; Flaherty KT
    Curr Opin Oncol; 2012 Mar; 24(2):150-4. PubMed ID: 22316627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strides in melanoma announced: maximizing value comes next.
    Tuma RS
    J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
    [No Abstract]   [Full Text] [Related]  

  • 15. Major therapeutic developments and current challenges in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Br J Dermatol; 2014 Jan; 170(1):36-44. PubMed ID: 24443912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
    J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 18. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.
    Ji Z; Njauw CN; Taylor M; Neel V; Flaherty KT; Tsao H
    J Invest Dermatol; 2012 Feb; 132(2):356-64. PubMed ID: 21993556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2/MDMX inhibitor peptide: WO2008106507.
    Macchiarulo A; Pellicciari R
    Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.